MX2009009856A - Sistemas transdérmicos de farmacos amorfos, métodos de elaboración y estabilizacion. - Google Patents

Sistemas transdérmicos de farmacos amorfos, métodos de elaboración y estabilizacion.

Info

Publication number
MX2009009856A
MX2009009856A MX2009009856A MX2009009856A MX2009009856A MX 2009009856 A MX2009009856 A MX 2009009856A MX 2009009856 A MX2009009856 A MX 2009009856A MX 2009009856 A MX2009009856 A MX 2009009856A MX 2009009856 A MX2009009856 A MX 2009009856A
Authority
MX
Mexico
Prior art keywords
stabilization
manufacturing methods
drug transdermal
present
transdermal systems
Prior art date
Application number
MX2009009856A
Other languages
English (en)
Inventor
Russell D Beste
Jiansheng Tang
Joseph M Deverich
Kenneth J Ii Miller
Original Assignee
Mylan Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39530666&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009009856(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mylan Technologies Inc filed Critical Mylan Technologies Inc
Publication of MX2009009856A publication Critical patent/MX2009009856A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un dispositivo de transportación transdérmica que comprende una capa de soporte, una capa de matriz adhesiva que comprende una concentración supersaturada de un agente activo en forma sustancialmente amorfa dentro de la matriz adhesiva, y un protector de liberación. La presente invención se refiere también a un método de preparación de una matriz adhesiva que contiene al menos un agente activo supersaturado en forma sustancialmente amorfa. Además, la presente invención se refiere a un método para estabilizar y un método para restablecer al sistema transdérmico de fármaco amorfo metaestable durante sus procesos de elaboración, almacenaje, transportación y manejo.
MX2009009856A 2007-03-16 2008-03-11 Sistemas transdérmicos de farmacos amorfos, métodos de elaboración y estabilizacion. MX2009009856A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/725,159 US20080226698A1 (en) 2007-03-16 2007-03-16 Amorphous drug transdermal systems, manufacturing methods, and stabilization
PCT/US2008/003221 WO2008115371A2 (en) 2007-03-16 2008-03-11 Amorphous drug transdermal systems, manufacturing methods, and stabilization

Publications (1)

Publication Number Publication Date
MX2009009856A true MX2009009856A (es) 2009-12-14

Family

ID=39530666

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009009856A MX2009009856A (es) 2007-03-16 2008-03-11 Sistemas transdérmicos de farmacos amorfos, métodos de elaboración y estabilizacion.

Country Status (15)

Country Link
US (1) US20080226698A1 (es)
EP (3) EP2848248A3 (es)
JP (2) JP2010521525A (es)
KR (2) KR101488458B1 (es)
CN (2) CN101674816B (es)
AU (1) AU2008227090B2 (es)
BR (1) BRPI0808864A2 (es)
CA (3) CA2947796A1 (es)
ES (1) ES2436290T3 (es)
HK (1) HK1134434A1 (es)
MX (1) MX2009009856A (es)
NZ (1) NZ580443A (es)
PL (1) PL2136795T3 (es)
PT (1) PT2136795E (es)
WO (1) WO2008115371A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017301B2 (en) 2007-09-04 2015-04-28 Mylan Technologies, Inc. Transdermal drug delivery systems comprising a coated release liner
JP2011513287A (ja) 2008-02-28 2011-04-28 シントロファーマ リミテッド 医薬品組成物
EP2285924B1 (en) * 2008-04-22 2014-06-11 3M Innovative Properties Company Adhesive article
DE102008021842A1 (de) * 2008-04-30 2009-11-05 Tesa Se Polyolefinfolie und Verwendung derselben
WO2009158120A2 (en) * 2008-05-30 2009-12-30 Mylan Laboratories Inc. Stabilized transdermal drug delivery system
EP2742934A1 (en) * 2008-10-06 2014-06-18 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
JP2010163367A (ja) * 2009-01-13 2010-07-29 Nitto Denko Corp 貼付剤および貼付製剤
US8920392B2 (en) 2009-05-05 2014-12-30 Watson Laboratories, Inc. Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions
DE102009052972A1 (de) * 2009-11-12 2011-09-15 Lts Lohmann Therapie-Systeme Ag Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm
ES2679800T3 (es) 2009-12-22 2018-08-31 Lts Lohmann Therapie-Systeme Ag Polivinilpirrolidona para la estabilización de una dispersión sólida de la forma no cristalina de rotigotina
JP5766475B2 (ja) * 2010-03-30 2015-08-19 日東電工株式会社 貼付製剤およびその製造方法
US8563031B2 (en) * 2010-05-27 2013-10-22 Absize, Inc. Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith
CN102038664A (zh) * 2010-12-20 2011-05-04 蚌埠丰原涂山制药有限公司 一种东莨菪碱透皮贴片及其制备方法
HRP20211377T1 (hr) 2011-11-23 2022-01-07 Therapeuticsmd, Inc. Prirodne kombinirane hormonske supstitucijske formulacije i terapije
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
EP2870963A4 (en) * 2012-07-06 2016-03-09 Sk Chemicals Co Ltd PREPARATION CONTAINING ROTIGOTINE FOR PERCUTANEOUS ABSORBING
JP5270035B1 (ja) * 2012-12-06 2013-08-21 久光製薬株式会社 貼付剤及びその製造方法
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
JP5307931B1 (ja) * 2012-12-27 2013-10-02 久光製薬株式会社 貼付剤及びその製造方法
CN103919755B (zh) * 2013-01-15 2019-10-18 江苏康倍得药业股份有限公司 妥洛特罗透皮贴剂及其制备方法
JP5415645B1 (ja) 2013-06-28 2014-02-12 久光製薬株式会社 貼付剤の製造方法、貼付剤及び包装体
CA2947767A1 (en) 2014-05-22 2015-11-26 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CN104208041B (zh) * 2014-08-28 2018-12-21 上海赛琅医药科技有限公司 一种用于预防、干预疤痕以及疤痕增生的可塑性硅凝胶和其制作方法
US10010543B1 (en) 2014-12-23 2018-07-03 Barr Laboratories, Inc. Transdermal dosage form
WO2016130408A1 (en) * 2015-02-09 2016-08-18 Dow Corning Corporation Multi-phase silicone acrylic hybrid visco-elastic compositions and methods of making same
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． ステロイドホルモン薬学的組成物
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
CN109689671A (zh) * 2016-08-12 2019-04-26 北卡罗来纳州大学 表面改性的聚合物
JP6663503B2 (ja) * 2016-10-11 2020-03-11 久光製薬株式会社 オキシブチニン含有経皮吸収製剤
EP3558275A1 (en) 2016-12-20 2019-10-30 LTS Lohmann Therapie-Systeme AG Transdermal therapeutic system containing asenapine
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
KR20180121352A (ko) 2017-04-28 2018-11-07 닛토덴코 가부시키가이샤 경피 흡수형 제제
EP3644973B1 (en) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
CN107320463A (zh) * 2017-07-10 2017-11-07 徐静 一种含有单硝酸异山梨酯的缓释透皮贴剂及其应用
CN111093638B (zh) * 2017-09-04 2024-03-26 罗曼治疗***股份公司 包含乳化剂的透皮递送***
DE102017127433A1 (de) * 2017-11-21 2019-05-23 Lts Lohmann Therapie-Systeme Ag TTS auf Basis von klebenden Weichmacher-Polymer-Matrices
JP7307731B2 (ja) * 2018-01-03 2023-07-12 コロプラスト アクティーゼルスカブ ストーマ周囲領域用スキンケア組成物
WO2019234662A1 (en) * 2018-06-07 2019-12-12 Nal Pharmaceutical Group Limited Transdermal drug delivery system containing rotigotine
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗***股份公司 含有阿塞那平的透皮治疗***
BR112021009074A2 (pt) 2018-11-09 2021-08-10 Sofresh, Inc. filme, método para fabricar um filme
GB2588612A (en) * 2019-10-28 2021-05-05 Univ Of Sunderland Transdermal patch
CN112891324A (zh) * 2021-01-19 2021-06-04 北京亚宝生物药业有限公司 一种透皮贴剂

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US516419A (en) * 1894-03-13 Means for the propulsion of vessels
US4022203A (en) * 1976-01-22 1977-05-10 Win Ackley Treated patch for minor cuts
DE2920500A1 (de) * 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim Pharmazeutische zubereitung in form eines polyacrylatfilmes
DE3204551A1 (de) * 1982-02-10 1983-08-18 Boehringer Ingelheim KG, 6507 Ingelheim Verfahren zur herstellung einer pharmazeutischen zubereitung in form eines polyacrylat-films
US4655767A (en) * 1984-10-29 1987-04-07 Dow Corning Corporation Transdermal drug delivery devices with amine-resistant silicone adhesives
US4880633A (en) * 1986-03-12 1989-11-14 Merck & Co., Inc. Transdermal drug delivery system
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
JPH066534B2 (ja) * 1986-10-09 1994-01-26 積水化学工業株式会社 経皮吸収貼付剤
US4832953A (en) * 1987-08-13 1989-05-23 Alza Corporation Method for preventing the formation of a crystalline hydrate in a dispersion of a liquid in a monaqueous matrix
US4814168A (en) * 1988-03-04 1989-03-21 Noven Pharmaceuticals, Inc. Transdermal multipolymer drug delivery system
JP2820306B2 (ja) * 1990-02-27 1998-11-05 積水化学工業株式会社 経皮吸収製剤
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5164190A (en) 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5676968A (en) * 1991-10-31 1997-10-14 Schering Aktiengesellschaft Transdermal therapeutic systems with crystallization inhibitors
IT1253265B (it) * 1991-11-25 1995-07-14 Rotta Research Lab Preparato a matrice copolimerica adesiva a base acrilica per il rilascio transdermico dell'estradiolo.
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
US6162456A (en) * 1992-09-24 2000-12-19 Ortho-Mcneil Pharmaceutical, Inc. Adhesive transdermal drug delivery matrix of a physical blend of hydrophilic and hydrophobic polymers
US5662928A (en) * 1995-04-21 1997-09-02 Ciba-Geigy Corporation Method for the prevention or removal of crystalline scopolamine in a non-aqueous matrix of a transdermal system
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
US5906830A (en) * 1995-09-08 1999-05-25 Cygnus, Inc. Supersaturated transdermal drug delivery systems, and methods for manufacturing the same
US6238700B1 (en) * 1995-12-01 2001-05-29 Alza Corporation Method for preventing crystal formation in a dispersion of a liquid in a matrix
EP0863751B1 (en) * 1995-12-01 2001-10-24 Alza Corporation Improved method for preventing crystal formation in a dispersion of a liquid in a matrix
DE19548332A1 (de) * 1995-12-22 1997-07-10 Rotta Res Bv Hormonpflaster
US6623763B2 (en) * 1996-01-08 2003-09-23 Lts Lohmann Therape-System Ag Pharmaceutical preparation adhering to the skin, in particular a transdermal therapeutic system for the release of 17-β-estradiol to the human organism
US5869089A (en) * 1996-03-21 1999-02-09 China-America Technology Corp. (Ctc) Manufacturing method of programmable transdermal therapeutic system
FR2749514B1 (fr) * 1996-06-11 1998-08-07 Hoechst Marion Roussel Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
GB9720470D0 (en) * 1997-09-25 1997-11-26 Ethical Pharmaceuticals South Inhibition of crystallization in transdermal devices
AU1728099A (en) 1997-12-22 1999-07-12 Alza Corporation Monoglyceride and ethyl palmitate permeation enhancer compositions
SE9801704D0 (sv) * 1998-05-14 1998-05-14 Bioglan Ab Biologically active composition
DE19827732A1 (de) * 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
DE19828273B4 (de) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
US6337086B1 (en) * 1999-02-06 2002-01-08 Dow Corning Corporation Pressure sensitive adhesive compositions for transdermal drug delivery devices
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
US6562368B2 (en) * 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of oxybutynin using hydroxide-releasing agents as permeation enhancers
WO2002045701A2 (en) * 2000-12-05 2002-06-13 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems
DE10060550C1 (de) 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
WO2003034961A1 (en) * 2001-10-23 2003-05-01 Euro-Celtique, S.A. Terazosin transdermal device and methods
DE10212864B4 (de) * 2002-03-22 2005-12-22 Beiersdorf Ag Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246979B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
JP4792193B2 (ja) * 2002-08-28 2011-10-12 久光製薬株式会社 貼付剤
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
PL1895994T3 (pl) * 2005-05-13 2011-02-28 Alza Corp Wielowarstwowy system podawania leków z barierą zabezpieczającą przed wypływaniem materiału ze zbiornika

Also Published As

Publication number Publication date
KR101488457B1 (ko) 2015-02-02
AU2008227090B2 (en) 2014-05-08
US20080226698A1 (en) 2008-09-18
CA2762981C (en) 2016-11-29
ES2436290T3 (es) 2013-12-30
EP2848248A3 (en) 2015-03-25
WO2008115371A2 (en) 2008-09-25
BRPI0808864A2 (pt) 2014-09-23
JP2010521525A (ja) 2010-06-24
CA2762981A1 (en) 2008-09-25
AU2008227090A1 (en) 2008-09-25
JP6068324B2 (ja) 2017-01-25
EP2136795B1 (en) 2013-09-04
KR20130030308A (ko) 2013-03-26
CN101674816A (zh) 2010-03-17
KR101488458B1 (ko) 2015-01-30
JP2014065727A (ja) 2014-04-17
PL2136795T3 (pl) 2014-02-28
CN106074455A (zh) 2016-11-09
EP2522339A2 (en) 2012-11-14
EP2522339A3 (en) 2014-01-22
HK1134434A1 (en) 2010-04-30
NZ580443A (en) 2012-07-27
CA2947796A1 (en) 2008-09-25
CN101674816B (zh) 2016-10-26
PT2136795E (pt) 2013-11-19
CA2679535C (en) 2014-09-09
CA2679535A1 (en) 2008-09-25
EP2848248A2 (en) 2015-03-18
EP2136795A2 (en) 2009-12-30
KR20090120498A (ko) 2009-11-24
WO2008115371A3 (en) 2009-08-27

Similar Documents

Publication Publication Date Title
MX2009009856A (es) Sistemas transdérmicos de farmacos amorfos, métodos de elaboración y estabilizacion.
WO2010042152A3 (en) Amorphous rotigotine transdermal system
WO2007035940A3 (en) Transdermal norelgestromin delivery system
WO2007035942A3 (en) Transdermal risperidone delivery system
NZ589542A (en) Transdermal drug delivery system comprising an active agent in amorphous form and polyvinylpyrrolidone
NZ703820A (en) Permeant delivery system and methods for use thereof
MX2010002452A (es) Sistema de entrega de medicamento transdermico que comprende una capa de liberacion recubierta.
CL2009001556A1 (es) Sistema de administración transdermica de fármacos que comprende una capa que contiene fármaco que comprende una matriz polimérica que contiene estradiol como unico fármaco; método de elaboración; útil para administrar estradiol.
WO2010041256A3 (en) A composition of matter comprising liposomes embedded in a polymeric matrix and methods of using same
MX2009012273A (es) Dispositivos de suministro transd?rmico que aseguran la liberaci?n mejorada de un principio activo a trav?s de una interfaz biol?gica.
WO2007035941A3 (en) Transdermal galantamine delivery system
NZ605352A (en) Process for producing glycosaminoglycans
WO2011029948A3 (de) Transdermales therapeutisches system zur verabreichung von fentanyl oder einem analogstoff davon
WO2011005421A3 (en) Use of nanocrystals for a drug delivery balloon
TW200628175A (en) Transdermal drug delivert device including an occlusive backing
WO2011139479A3 (en) High shear application in drug delivery
PE20071163A1 (es) Dispositivo de liberacion transdermica de meptazinol
WO2010080575A3 (en) Method and apparatus for transport of substances into body tissue
MX2012014060A (es) Sistema de suministro de ingredientes activos.
CL2012002909A1 (es) Procedimiento de preparación de una composición farmacéutica que comprenden a) un centro granulado constituido por granos de principio activo aglomerados en presencia de aglomerante y b) una capa de recubrimiento de dicho centro granulado constituido por matriz grasa; composición farmacéutica; y su uso para administración oral
IN2012DN00845A (es)
JP6335790B2 (ja) 自発的に結晶化する傾向が低い経皮治療システム
MX2009014102A (es) Sistema de administración transdérmica que comprende glicopirrolato para tratar sialorrea.
GB2483505B (en) Devices for transdermal drug delivery
WO2012091408A3 (en) Matrix type antimicrobial vehicle and manufacturing method thereof

Legal Events

Date Code Title Description
FG Grant or registration